Abstract : The glutamate receptors in the nervous system are related to nociceptive response. These receptors include the AMPA (a -amino-3-hydroxy-5-methyl-4-isoxazolepropionate) receptor and the NMDA (N-methyl-D-aspartate) receptor1). Under light ether anesthesia, a caudal cutaneous vertical incision (1 cm in length) was made to facilitate lumbar puncture. We waited at least 1 hour, and then intrathecal injections of saline as a control, Ly293558 or Ly233053 in fully awake rats (n = 5 for each injection), were performed with a 27 gauge needle between the L5 and L6 vertebrae. Appropriate doses of these antagonists were determined in a preliminary study. A single dose of each of the antagonists was selected in order to produce mild antinociceptive effects that would not produce behavioral responses5). The concentrations of Ly293558 (the novel AMPA antagonist, 0.1 pmol to 10 pmol) and Ly233053 (the novel NMDA antagonist, 10 pmol to 1000 pmol) used did not produce motor dysfunction or behavioral responses. All agents were dissolved in 50 p1 of saline and given intrathecally 15 min prior to formalin injection.
For nociceptive testing, rats were given a standard subcutaneous injection of 50 pl of 2.0% formalin into the plantar surface of one hindpaw. Rats were then placed in a 30 cm X 30 cm X 30 cm Plexiglas box. We measured the total time the animal spent licking the hindpaw in the first 5 min (early phase) and from 10 to 30 min (late phase) after formalin injection.
We observed animals for 2 hours. The following morning we examined animals for evidence of motor dysfunction such as gait disturbance.
Then rats were sacrificed by intracardiac injection of KCl 2 mEq in 1 ml under ether anesthesia. The data were analyzed using one-way ANOVA. We considered differences statistically significant when the p value was less than 0.05. The early phase of the formalin test may be due to immediate and direct effects on sensory response (peripheral sensitization) and the late phase due to inflammatory response at injection site (central sensitization). Neural activity generated during the early phase of the formalin response can induce changes in CNS function (i.e., central sensitization), which in turn influence processing during the late phase. Woolf and Thompson7) showed that a brief nociceptive input causes prolonged increases in central excitation as gauged by rat hind limb flexion reflex activity. Endogenous release of EAAs may lead to the development of neuroplasticity in spinal nociceptive neurons following an intense nociceptive stimulus, and lead to the development of persistent nociception, as occurs following formalin injection. EAA treatment does not simply produce a static hyperalgesic effect that adds to formalin nociception throughout testing, but rather it shifts the late phase of the formalin test to an earlier time point. It has been proposed that long-term potentiation (LTP ; a kind of neuroplasticity that changes synaptic function), is due both to an increase in neurotransmitter release and to an enhanced postsynaptic AMPA/kinate response10)
Haley, Sullivan and Dickenson 11) demonstrated in mice that pretreatment with intrathecal AP-5, a competitive NMDA antagonist, or intravenous MK-801, a non-competitive NMDA antagonist, produced a marked inhibition of dorsal horn activity in the late phase after subcutaneous formalin injection, but only induced small nonsignificant effects on activity during the early phase. However, the behavioral response to formalin stimulation in rats showed an antinociceptive effect of the non-competitive NMDA antagonist, MK-801, on both the first and the second phase of the formalin test, although it was more potent against the second phase response 12,13) . In mice, several AMPA antagonists, such as CNQX, DNQX and competitive NMDA antagonists, such as AP5, AP7 and CPP, reduced the early phase formalin response in behavioral tests 14) (the late phase was not tested).
Our present results show that Ly 2935558, an AMPA-kainate antagonist (0.1-10 pmol ), and Ly 233053, an NMDA antagonist (10-1000 pmol), significantly and dose-dependently reduced the duration of licking time in the early phase. Whereas in the late phase, only the highest doses of AMPA antagonist (10 pmol) and NMDA antagonist (1000 pmol ) significantly reduced the licking time's.
Why do these antagonists have more of an effect in the early phase that the late phase?
These results may be due to the pharmacological characteristics of these agents, such as a rapid onset and a short duration of action. It has been shown that Ly 233053, a potent and selective antagonist of NMDA receptors, possesses a rapid onset, a relatively short duration and neuroprotective effect in the treatment of acute conditions such as cerebral ischemia16).
No motor dysfunction was observed at the dosages we used. Paresis of the hind limb had developed at 100-fold higher concentrations of these agents in a preliminary study. Schoepp et In lamina II and the superficial part of lamina III in the rat spinal cord, dense areas of neurons relating to nociception are present. The expression of GluR2 is especially high in this region, suggesting that such high expression is a characteristic of the AMPA type receptor involved in nociception. It has been shown that Ly 293558 inhibits [3H]-AMPA ligand binding and AMPA-induced depolarization 11)
.
A recent study clearly showed that AMPA-KA receptors play a role in pain transmission in humansl8) .
Intravenously administered Ly 293558 significantly decreased both spontaneous pain and the spread of mechanical hyperalgesia evoked by intradermal capsicin, but did not significantly reduce brief suprathreshold pain sensations in normal skin. Based on the differential analgesic response between two human experimental models of pain, it was suggested that AMPA-KA receptors primarily contribute to the processes leading to sensitization of central neurons (phase II).
The observation that Ly 293558 reduces pain and allodynia in the capsaicin model has implications for therapy. Mechanical allodynia and hyperalgesia are often seen in patients with acute pain after surgery and chronic pain after nerve or soft tissue injuries, and quantitative sensory testing in many such patients suggests central neural sensitization. N-methyl-D-aspartate receptor blockade has reduced pain in some of these patients but has been accompanied by side effects that usually prevent complete relief 18). 
